At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
Herpes Zoster Vaccine 1437173A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
In Brief
A Phase 2 clinical trial evaluating Herpes Zoster Vaccine 1437173A and Placebo vaccine (saline) for Herpes Zoster. Completed, enrolled 121 participants across 11 sites.
Detailed Summary
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartJul 2009
Primary CompletionApr 2011
Study CompletionMar 2012
TodayJul 2026
First PostedJun 15, 2009
Enrollment StartJul 14, 2009
Primary CompletionApr 26, 2011
Study CompletionMar 21, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.0 years ago
Interventions
Herpes Zoster Vaccine 1437173Abiological
Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
Placebo vaccine (saline)biological
1 or 3 doses of Placebo (saline) injected intramuscularly.